- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01119638
Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone (EscBPSD)
Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients
Behavioral and psychological symptoms of dementia (BPSD) are among the most distressing manifestations of dementia. Pharmacotherapy is frequently used and especially in institutional settings. Current guidelines recommend the use of second-generation antipsychotics (SGAs). Nonetheless, there are concerns regarding both their safety and effectiveness in patients with dementia. Inconclusive evidence support the use of other psychoactive agents such as SSRI antidepressants or cognitive enhancers.
In two published studies citalopram was as efficacious as, but better tolerated than perphenazine or risperidone in patients with BPSD.
Thus, with proven efficacy and a beneficial safety profile the evaluation of the use of escitalopram for BPSD is warranted.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Behavioral and psychological symptoms of dementia (BPSD) as agitation or psychosis are among the most distressing manifestations of dementia. The evidence-based management of these symptoms includes the search for treatable physical and environmental precipitants, support and psychoeducation for primary caregivers and psychosocial interventions. Nevertheless, pharmacotherapy is frequently used and especially in institutional settings. Current guidelines recommend the use of second-generation antipsychotics (SGAs). Nonetheless, there are concerns regarding both their safety and effectiveness in patients with dementia. Recent research has resulted in a 'black-box" warning concerning the safety of using SGAs for BPSD. Sparse and inconclusive evidence support the use of other psychoactive agents such as SSRI antidepressants or cognitive enhancers.
In two published randomized controlled trials, citalopram was more efficacious than placebo and as efficacious as, but better tolerated than perphenazine or risperidone in patients with dementia hospitalized for the treatment of agitation or psychosis.
Thus, with proven efficacy and a beneficial safety profile the evaluation of the use of escitalopram for BPSD is warranted.
A 6-week parallel groups, randomized, controlled trial in patients with dementia hospitalized because of behavioral symptoms will be conducted at the Abarbanel MHC.
Participants will be consecutively recruited on an inpatient unit. Randomization will be based on a table of random numbers held centrally by an uninvolved physician.
The study will be of a "double-blind" design. All medications in identical packaging will be distributed to the ward from a central pharmacy.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bat-Yam, Israel, 59100
- Abarbanel MHC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Eligible participants will fulfill criteria for dementia of the Alzheimer's type (according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition). The score on the Mini-Mental State Examination (MMSE) has to be between 5 and 26.
Eligible patients will suffer from delusions, hallucinations, aggression, or agitation that developed after the onset of dementia and is severe enough to disrupt their functioning and, in the opinion of the study physicians, to justify treatment with antipsychotic drugs.
Signs and symptoms of psychosis, aggression, or agitation will have to occur nearly daily during the week prior to enrollment.
A frequency rating of "often" or "more frequently" and a severity rating of at least "moderate" are required for delusions, hallucinations, agitation, or "aberrant motor behavior" in the Neuropsychiatric Inventory (NPI).
Exclusion Criteria:
Patients will be excluded if they had received a diagnosis of a primary psychotic disorder (e.g., schizophrenia), delirium, other dementia. Patients will also be excluded if they were going to receive treatment with a cholinesterase inhibitor or antidepressant medication, had previously been treated with escitalopram for BPSD, or had contraindications to the two study drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Escitalopram Drug
Drug: Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion. |
Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
Other Names:
|
Active Comparator: Risperidone Drug
Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
|
Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in total score on the NPI.
Time Frame: from first treatment to end of study at 6 weeks
|
from first treatment to end of study at 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from initial treatment to the discontinuation of treatment for any reason.
Time Frame: time to discontinuation for any reason
|
we shall consider any reason for stopping the study medications to be avalid reason for "discontinuation.
This measure was deemed important by the NIH for dementia drug studies.
|
time to discontinuation for any reason
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yoram Barak, MD, MHA, Abarbanel MHC, Israel.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Psychomotor Disorders
- Dementia
- Tauopathies
- Psychotic Disorders
- Psychomotor Agitation
- Mental Disorders
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Antidepressive Agents, Second-Generation
- Citalopram
- Risperidone
Other Study ID Numbers
- ABR-BPSD-001
- CO01ABR01022008 (Other Grant/Funding Number: Lundbeck A/S)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingEarly PsychosisUnited States
-
Yale UniversityCompleted
-
University of TorontoUniversity of British Columbia; Centre for Addiction and Mental Health; Queen... and other collaboratorsNot yet recruitingPsychotic Disorders | Schizophrenia | Psychosis | Schizophrenia; Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
State reference center for psychosocial careUniversity of ValenciaCompleted
Clinical Trials on Escitalopram
-
First Affiliated Hospital of Zhejiang UniversityRecruitingAdolescent | Depressive DisorderChina
-
Perry RenshawTerminatedDepression | Substance Use | Dual DiagnosisUnited States
-
University of NebraskaRecruiting
-
Rigshospitalet, DenmarkUniversity of Cambridge; Lundbeck FoundationCompleted
-
Ryerson UniversityUnknownInsomnia | Major Depressive DisorderCanada
-
Centre Hospitalier Universitaire VaudoisNot yet recruitingPharmacogenetic Testing
-
Shanghai 7th People's HospitalNot yet recruitingDepressive Disorder, MajorChina
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
Shanghai Mental Health CenterRecruiting
-
University of PennsylvaniaWashington University School of MedicineCompleted